Julie Vose

35PUBLICATIONS
318CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical genetics (excl. cancer genetics)Immunology not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Feb 26, 2026
Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

James O Armitage, Matthew A Lunning, Julie M Vose

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

|Nov 05, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Sunandini Sharma, Roshia Ali, Alyssa Bouska

|Oct 17, 2025
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Waseem G Lone, Jiayu Yu, Xuxiang Liu

|Sep 24, 2025
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.

Paula M Fracasso, Nicole L Simone, Stephanie J Si Lim

Pageof 6

Frequent Collaborators

6 joint publications

Stefano Pileri

5 joint publications

Abhinav Deol

4 joint publications

Wing C Chan

4 joint publications

Olalekan Oluwole